{"collection_id":"acrin_nsclc_fdg_pet","collection_name":"ACRIN-NSCLC-FDG-PET","cancer_types":"Non-small Cell Lung Cancer","tumor_locations":"Lung","species":"Human","subjects":242,"supporting_data":"Clinical","description":"Thirty-seven institutions accrued 250 patients to the study ACRIN 6668. Eligible patients were >18\nyears with AJCC-criteria clinical stage IIB/III non-small cell lung carcinoma who were being planned\nfor definitive concurrent chemoradiotherapy (inoperable disease). 173 had evaluable post-treatment\nPET, representing the analysis cohort for the primary end point.\nPlease see the ACRIN-NSCLC-FDG-PET (https://doi.org/10.7937/tcia.2019.30ilqfcl) wiki page to learn\nmore about the images and to obtain any supporting metadata for this collection.","patients":242,"studies":950,"series":3762,"instances":497752,"size_TB":0.146,"modalities":["CR","CT","DX","MR","NM","OT","PT","SEG"],"licenses":[{"license_short_name":"CC BY 3.0","series":3377,"size_TB":0.145},{"license_short_name":"CC BY 4.0","series":385,"size_TB":0.0}]}